text_1: Cancers that initially benefit from epidermal growth factor receptor targeted therapies later become refractory through several mechanisms.
text_2: We present a comprehensive review of resistance pathways to EGFR-targeted therapies in lung, colorectal and head and neck cancers and discuss therapeutic strategies that are designed to circumvent resistance.